openPR Logo
Press release

Paroxysmal Nocturnal Hemoglobinuria Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis, Regeneron Pharma, RA Pharma, Alexion

06-11-2024 03:38 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Paroxysmal Nocturnal Hemoglobinuria Pipeline and Clinical

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Paroxysmal Nocturnal Hemoglobinuria pipeline constitutes 20+ key companies continuously working towards developing 25+ Paroxysmal Nocturnal Hemoglobinuria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Paroxysmal Nocturnal Hemoglobinuria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Paroxysmal Nocturnal Hemoglobinuria Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Paroxysmal Nocturnal Hemoglobinuria Market.

Some of the key takeaways from the Paroxysmal Nocturnal Hemoglobinuria Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Paroxysmal Nocturnal Hemoglobinuria treatment therapies with a considerable amount of success over the years.

*
Paroxysmal Nocturnal Hemoglobinuria companies working in the treatment market are Amyndas Pharmaceuticals, Arrowhead Pharmaceuticals, Kira Pharmaceuticals (US), LLC., Alexion AstraZeneca Rare Disease, Regeneron Pharmaceuticals, and others, are developing therapies for the Paroxysmal Nocturnal Hemoglobinuria treatment

*
Emerging Paroxysmal Nocturnal Hemoglobinuria therapies in the different phases of clinical trials are- AMY 101, ARO-C3, KP104, Danicopan, Pozelimab, and others are expected to have a significant impact on the Paroxysmal Nocturnal Hemoglobinuria market in the coming years.

*
In December 2023, Kira Pharmaceuticals, a worldwide biotech company developing groundbreaking complement therapies for immune-mediated diseases, shared interim safety and efficacy findings from its Phase 2 study of KP104 in complement inhibitor-naive PNH patients. This was presented orally at the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego on December 10th. Additionally, the presentation has been chosen for inclusion in the 2024 Highlights of ASH. KP104 is a pioneering bifunctional biologic designed to inhibit both the alternative and terminal complement pathways.

*
In March 2023, Regeneron Pharmaceuticals has started a trial named "An Open-Label Extension Study for Assessing the Extended Safety, Tolerance, and Effectiveness of Pozelimab and Cemdisiran Combined Treatment in Individuals Affected by Paroxysmal Hemoglobinuria." The main goal of this study is to outline the extended-term safety, tolerance, and effectiveness of the combined therapy involving Pozelimab and Cemdisiran in patients diagnosed with PNH. Presently, the trial is ongoing, involving 300 participants, and it's expected to conclude by March 2028.

Paroxysmal Nocturnal Hemoglobinuria Overview

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired, life-threatening disease of the blood. It is characterized by the destruction of red blood cells (hemolysis), blood clots (thrombosis), and impaired bone marrow function. PNH is caused by a mutation in the PIGA gene in a hematopoietic stem cell, leading to the production of defective blood cells that are more prone to being attacked by the immune system.

Get a Free Sample PDF Report to know more about Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight [https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Paroxysmal Nocturnal Hemoglobinuria Drugs Under Different Phases of Clinical Development Include:

*
AMY 101: Amyndas Pharmaceuticals

*
ARO-C3: Arrowhead Pharmaceuticals

*
KP104: Kira Pharmaceuticals (US), LLC.

*
Danicopan: Alexion AstraZeneca Rare Disease

*
Pozelimab: Regeneron Pharmaceuticals

Paroxysmal Nocturnal Hemoglobinuria Route of Administration

Paroxysmal Nocturnal Hemoglobinuria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravitreal

*
Subretinal

*
Topical

*
Molecule Type

Paroxysmal Nocturnal Hemoglobinuria Molecule Type

Paroxysmal Nocturnal Hemoglobinuria Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

*
Product Type

Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics Assessment

*
Paroxysmal Nocturnal Hemoglobinuria Assessment by Product Type

*
Paroxysmal Nocturnal Hemoglobinuria By Stage and Product Type

*
Paroxysmal Nocturnal Hemoglobinuria Assessment by Route of Administration

*
Paroxysmal Nocturnal Hemoglobinuria By Stage and Route of Administration

*
Paroxysmal Nocturnal Hemoglobinuria Assessment by Molecule Type

*
Paroxysmal Nocturnal Hemoglobinuria by Stage and Molecule Type

DelveInsight's Paroxysmal Nocturnal Hemoglobinuria Report covers around 25+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Paroxysmal Nocturnal Hemoglobinuria product details are provided in the report. Download the Paroxysmal Nocturnal Hemoglobinuria pipeline report to learn more about the emerging Paroxysmal Nocturnal Hemoglobinuria therapies [https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market include:

Key companies developing therapies for Paroxysmal Nocturnal Hemoglobinuria are - Alexion Pharmaceuticals, Apellis Pharmaceuticals, Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, RA Pharmaceuticals Inc., and others.

Paroxysmal Nocturnal Hemoglobinuria Pipeline Analysis:

The Paroxysmal Nocturnal Hemoglobinuria pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Paroxysmal Nocturnal Hemoglobinuria with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Paroxysmal Nocturnal Hemoglobinuria Treatment.

*
Paroxysmal Nocturnal Hemoglobinuria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Paroxysmal Nocturnal Hemoglobinuria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Paroxysmal Nocturnal Hemoglobinuria market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Paroxysmal Nocturnal Hemoglobinuria drugs and therapies [https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Paroxysmal Nocturnal Hemoglobinuria Pipeline Market Drivers

*
Treatment approach for Paroxysmal Hemoglobinuria is rapidly evolving, increasing adoption of novel therapeutics and rising geriatric population are some of the important factors that are fueling the Paroxysmal Nocturnal Hemoglobinuria Market.

Paroxysmal Nocturnal Hemoglobinuria Pipeline Market Barriers

*
However, high treatment cost, reimbursement Policies and other factors are creating obstacles in the Paroxysmal Nocturnal Hemoglobinuria Market growth.

Scope of Paroxysmal Nocturnal Hemoglobinuria Pipeline Drug Insight

*
Coverage: Global

*
Key Paroxysmal Nocturnal Hemoglobinuria Companies: Amyndas Pharmaceuticals, Arrowhead Pharmaceuticals, Kira Pharmaceuticals (US), LLC., Alexion AstraZeneca Rare Disease, Regeneron Pharmaceuticals, and others

*
Key Paroxysmal Nocturnal Hemoglobinuria Therapies: AMY 101, ARO-C3, KP104, Danicopan, Pozelimab, and others

*
Paroxysmal Nocturnal Hemoglobinuria Therapeutic Assessment: Paroxysmal Nocturnal Hemoglobinuria current marketed and Paroxysmal Nocturnal Hemoglobinuria emerging therapies

*
Paroxysmal Nocturnal Hemoglobinuria Market Dynamics: Paroxysmal Nocturnal Hemoglobinuria market drivers and Paroxysmal Nocturnal Hemoglobinuria market barriers

Request for Sample PDF Report for Paroxysmal Nocturnal Hemoglobinuria Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Paroxysmal Nocturnal Hemoglobinuria Report Introduction

2. Paroxysmal Nocturnal Hemoglobinuria Executive Summary

3. Paroxysmal Nocturnal Hemoglobinuria Overview

4. Paroxysmal Nocturnal Hemoglobinuria- Analytical Perspective In-depth Commercial Assessment

5. Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics

6. Paroxysmal Nocturnal Hemoglobinuria Late Stage Products (Phase II/III)

7. Paroxysmal Nocturnal Hemoglobinuria Mid Stage Products (Phase II)

8. Paroxysmal Nocturnal Hemoglobinuria Early Stage Products (Phase I)

9. Paroxysmal Nocturnal Hemoglobinuria Preclinical Stage Products

10. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Assessment

11. Paroxysmal Nocturnal Hemoglobinuria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Paroxysmal Nocturnal Hemoglobinuria Key Companies

14. Paroxysmal Nocturnal Hemoglobinuria Key Products

15. Paroxysmal Nocturnal Hemoglobinuria Unmet Needs

16 . Paroxysmal Nocturnal Hemoglobinuria Market Drivers and Barriers

17. Paroxysmal Nocturnal Hemoglobinuria Future Perspectives and Conclusion

18. Paroxysmal Nocturnal Hemoglobinuria Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=paroxysmal-nocturnal-hemoglobinuria-pipeline-and-clinical-trials-assessment-2024-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-novartis-regeneron-pharma-ra-pharma-alexion]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Paroxysmal Nocturnal Hemoglobinuria Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis, Regeneron Pharma, RA Pharma, Alexion here

News-ID: 3534909 • Views:

More Releases from ABNewswire

Metering Pumps MarketSize, Opportunities, Top Companies Analysis, Growth, Trends, Regional Insights, Key Segments, and Forecast To 2028
Metering Pumps MarketSize, Opportunities, Top Companies Analysis, Growth, Trends …
The Metering Pumps Market is experiencing substantial regional growth in Asia-Pacific. This expansion is fueled by increasing industrialization, water treatment demands, and stringent chemical dosing requirements, driving the adoption of precise and reliable metering pump technologies. The global metering pumps market [https://www.marketsandmarkets.com/Market-Reports/metering-pump-market-949.html#:~:text=Metering%20Pumps%20Market%20Overview,automatically%20as%20per%20the%20requirement.] is approximated to be USD 6.9 billion in 2023, and it is projected to reach USD 8.5 billion by 2028 at a CAGR of 4.3%. Metering pumps play a
"The Vision Advantage" Now Available for Preorder
Discover "The Vision Advantage: How to Curb Quiet Quitting, Build Resilience, and Create Growth." extensive research into the visionary statements of Fortune 100 companies provides readers with a revolutionary perspective on the fundamental drivers of sustained, positive growth. New York, New York - June 19, 2024 - From the tribal regions of Pakistan to the capitals of Europe, Dr. Aaron Bazin [https://www.linkedin.com/in/aaronbazin] has emerged as a strategic visionary over nearly two
Park Avenue Surgeon, Dr. Anil Shah, Pioneers Advancements in Minimally Invasive Revision Rhinoplasty with Groundbreaking Research
Park Avenue Surgeon, Dr. Anil Shah, Pioneers Advancements in Minimally Invasive …
New York, NY - 19 June, 2024 - Nestled in the heart of Manhattan, Dr. Anil Shah, a renowned facial plastic surgeon, is making waves with his latest research on minimally invasive revision rhinoplasty [https://www.nosesandnecksnyc.com/]. Published recently, his article sheds light on safer, subtler techniques that promise significant improvements for those disillusioned by past nasal surgeries, without the ordeal of major reconstructive work. Image: https://lh7-us.googleusercontent.com/docsz/AD_4nXdpSscac2Y5NKZunhLAOFCYze1utsd-WvleOovkV2p2zHu9Bwn5F2QGp7pG3dPZJe2IBKA7b41hUwv_driov7SfMnGxmWsRPxEE1xYZdjWTA6fzOOinmayQwYF_sELtjfuVLqdgf5LA04cz3B2AI-5-l-av?key=AdmGG6tQtg0YfJbtoiqKUw Dr. Anil Shah, MD Noses and Necks NYC 60
Mango Animate's AI Video Creator Attracts Content Creators with Powerful Features
Mango Animate's AI Video Creator Attracts Content Creators with Powerful Feature …
Mango AI, developed by Mango Animate, is an AI video creator that attracts thousands of content creators with its human-like avatars and ease of use. Mango Animate's AI video creator [https://mangoanimate.com/?utm_source=abnewswire&utm_medium=PR&utm_campaign=ai-24061901], Mango AI, continues to impress content creators with its disruptive features that have kept it ahead of the competition. This AI video maker has simplified the process of making videos by eliminating the need for expensive studios and equipment while

All 5 Releases


More Releases for Paroxysmal

Paroxysmal Nocturnal Hemoglobinuria Market Report 2020-2030
Forecasts by Treatment (Medication, Stem Cell Transplant, Blood Transfusion) Plus Analysis of Leading Companies Download free sample pages: https://www.visiongain.com/report/paroxysmal-nocturnal-hemoglobinuria-market-report-2020-2030/ Paroxysmal Nocturnal Hemoglobinuria Market- our new study reveals trends, R&D progress, and predicted revenues Where the Paroxysmal Nocturnal Hemoglobinuria is market heading? If you are involved in this industry you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects
Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Companies , H2 2017
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017” Paroxysmal Nocturnal Hemoglobinuria   Overview Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier than normal. Symptoms include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache and shortness of breath. The predisposing factors include age, obesity and hormone therapy. Treatment
Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017
"The Report Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline landscape. Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier
Paroxysmal Nocturnal Hemoglobinuria Pipeline Insight and Therapeutic Assessment …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Paroxysmal Nocturnal Hemoglobinuria-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Paroxysmal Nocturnal Hemoglobinuria. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Paroxysmal Nocturnal Hemoglobinuria by development stage, therapy type,
Paroxysmal Nocturnal Hemoglobinuria Therapeutic Pipeline Analysis, 2017 Clinical …
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare life-threatening disease characterized by destruction of red blood cells, blood clots, and compromised bone marrow function. Some of the symptoms of the disease include abdominal and back pain, dark urine, easy bruising or bleeding, fatigue or weakness, headache and shortness of breath. The risk factors for PNH include age, obesity and hormone therapy. According to the Johns Hopkins Medicine, approximately, one to one
Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline landscape. Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier